TRANSCELERATE BIOPHARMA INC: Form 990, tax year 2014
View the entire original 990 at ProPublica ↗
- Organization
- TRANSCELERATE BIOPHARMA INC (EIN 46-0886344)
- Tax period
- 2014-01-01 to 2014-12-31
- Filed
- 2015-05-11
- IRS object ID
- 201511319349300436
- Schema version
- 2014v5.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2015-05-11T10:01:59-05:00 | ReturnTs |
| Tax Period End | 2014-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 131639826 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | EISNERAMPER LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 WEST AVENUE PO BOX 458 | AddressLine1Txt |
| City | JENKINTOWN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 190460458 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2014-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 460886344 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TRANSCELERATE BIOPHARMA INC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | TRAN | BusinessNameControlTxt |
| Phone | 6102706394 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 709 SWEDELAND ROAD NO UW2103 | AddressLine1Txt |
| City | KING OF PRUSSIA | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19406 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DALVIR GILL PHD | PersonNm |
| Person Title | CEO | PersonTitleTxt |
| Phone | 6102706394 | PhoneNum |
| Signature | 2015-05-07 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | STEVEN GLUECK | PreparerPersonNm |
| PTIN | P00856557 | PTIN |
| Phone | 2158818800 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2014 | TaxYr |
| Build TS | 2016-02-25 16:41:14Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | DALVIR GILL PHD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 709 SWEDELAND ROAD NO UW2103 | AddressLine1Txt |
| City | KING OF PRUSSIA | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19406 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $15,293,388 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c | Yes (X) | Organization501cInd |
| Website Address | WWW.TRANSCELERATEBIOPHARMAINC.COM | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2012 | FormationYr |
| Legal Domicile State | PA | LegalDomicileStateCd |
| Activity Or Mission | IMPROVE THE HEALTH OF PEOPLE IN THE WORLD BY ENHANCING THE R&D OF INNOVATIVE THERAPIES.TRANSCELERATE BIOPHARMA INC. IS A NON-PROFIT ORGANIZATION DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES. THE ORGANIZATIONS' MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, PRIORITIZE, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES. TRANSCELERATE EVOLVED FROM DISCUSSIONS AT VARIOUS FORUMS FOR EXECUTIVE R&D LEADERSHIP TO DEBATE CURRENT ISSUES FACING THE INDUSTRY, AND EXAMINE SOLUTIONS FOR ADDRESSING AGREED-UPON COMMON CHALLENGES. MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 17 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 16 | VotingMembersIndependentCnt |
| Total Employee | 4 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $0 | PYContributionsGrantsAmt |
| CY Contributions Grants | $0 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $13,630,000 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $15,276,176 | CYProgramServiceRevenueAmt |
| PY Investment Income | $13,765 | PYInvestmentIncomeAmt |
| CY Investment Income | $17,212 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $13,643,765 | PYTotalRevenueAmt |
| CY Total Revenue | $15,293,388 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $0 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $0 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $1,109,529 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $2,052,132 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $5,713,774 | PYOtherExpensesAmt |
| CY Other Expenses | $9,728,191 | CYOtherExpensesAmt |
| PY Total Expenses | $6,823,303 | PYTotalExpensesAmt |
| CY Total Expenses | $11,780,323 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $6,820,462 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $3,513,065 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $9,075,300 | TotalAssetsBOYAmt |
| Total Assets EOY | $34,898,547 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $1,902,607 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $24,786,391 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $7,172,693 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $10,112,156 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | TRANSCELERATE BIOPHARMA INC. IS DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES.THE ORGANIZATIONS' MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, PRIORITIZE, TO COLLABORATE ACROSS THE DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES. TRANSCELERATE EVOLVED FROM DISCUSSIONS AT VARIOUS FORUMS FOR EXECUTIVE R&D LEADERSHIP TO DEBATE CURRENT ISSUES FACING THE INDUSTRY, AND EXAMINE SOLUTIONS FOR ADDRESSING AGREED-UPON COMMON CHALLENGES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. | MissionDesc |
| Significant New Program Srvc | Yes (1) | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $7,854,129 | ExpenseAmt |
| Revenue | $15,276,176 | RevenueAmt |
| Desc | TRANSCELERATE EXPERIENCED SEVERAL SIGNIFICANT ACCOMPLISHMENTS IN 2014. SPECIFICALLY:CLINICAL DATA TRANSPARENCY- PUBLISHED CSR REDACTION APPROACH PAPER ON TRANSCELERATE WEBSITE IN SEPTEMBERCOMMON PROTOCOL TEMPLATE- CREATED A STRUCTURE FOR THE HUMAN READABLE TEMPLATE AND VISION FOR COMPUTABLE PROTOCOL- CONNECTED WITH OTHER PROTOCOL INITIATIVES, LEADING TO A COLLABORATIVE WORKSHOP AND PROPOSAL FOR AN EPROTOCOL STEERING COMMITTEE WITH MEMBERS FROM CDISC, FDA, EMA AND OTHER KEY STAKEHOLDERSINVESTIGATOR REGISTRY- SELECTED VENDOR TO DEVELOP INVESTIGATOR REGISTRY.- CONDUCTED SURVEY WITH MEMBER COMPANIES ON WILLINGNESS TO SHARE DATA ELEMENTS IN THE INVESTIGATOR REGISTRYRISK BASED MONITORING- ENGAGED WITH FDA IN SEPTEMBER TO DISCUSS RBM LESSONS LEARNED AND METRICS 1 YEAR POST-PILOT; - COMPLETED COMMITMENT TO SUBMIT 8 PILOTS TO FDA.- AS OF OCTOBER, 54 RBM PILOTED TRIALS ACROSS 10 MEMBER COMPANIES HAVE BEEN INITIATED.SITE QUALIFICATION & TRAINING- 11 MEMBER COMPANIES AND 90+ EXTERNAL TRAINING PROVIDERS HAVE ATTESTED THAT THEIR GCP TRAINING COURSES MEET THE MUTUALLY RECOGNIZED MINIMUM CRITERIA. - 74,000+ GCP TRAINING COMPLETION CERTIFICATES ISSUED BY 9 MEMBER COMPANIES.SHARED INVESTIGATOR PLATFORM- COMPLETED SHARED INVESTIGATOR PLATFORM (SIP) CORE PRODUCT RELEASE 1 (SIP [R1]) REQUIREMENTS; INITIATED DETAILED DESIGN, BUILD, AND INTEGRATED TESTING AND QUALIFICATION ACTIVITIES. ENGAGED EXTERNAL SITE USERS (SCRS SITE ADVOCACY GROUP) IN SIP DESIGN AND TESTING.- CONTINUING TO ALIGN SYSTEM REQUIREMENTS WITH INVESTIGATOR REGISTRY AND SITE QUALIFICATION & TRAINING WORKSTREAMS. | Desc |
| Total Program Service Expenses | $7,854,129 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | 0 | DescribedInSection501c3Ind |
| Schedule B Required | 0 | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Subject To Proxy Tax | Yes (1) | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | 0 | ForeignActivitiesInd |
| More Than5000 K To Org | 0 | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | 0 | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 13 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 4 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 17 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 16 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | Yes (1) | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (1) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (1) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | 0 | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | 0 | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | 0 | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ANTHONY GARGES FINANCE LEAD | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 6102706394 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 709 SWEDELAND ROAD | AddressLine1Txt |
| City | KING OF PRUSSIA | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19406 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (24 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Key EmployeeKeyEmployeeInd |
|---|---|---|---|---|---|---|---|
| ANNALISA JENKINS THRU 92014 | |||||||
| CHAIR OF BOARD OF DIRECTOR | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| STEVEN C GILMAN | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| MICHAEL SEVERINO | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| DAVID NICHOLSON | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| BRIAN DANIELS THRU 92014 | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| BRIGGS MORRISON EFF 92014 | |||||||
| CHAIR OF BOARD OF DIRECTORS | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| CORSEE SANDERS | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| ELIAS ZERHOUNI | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| GARRY NEIL | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| JAN LUNDBERG | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| JOHN HUBBARD THRU 122014 | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| KLAUS DUGI | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| MARCO TAGLIETTI THRU 92014 | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| PATRICK VALLANCE | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| PAUL STOFFELS | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| PETER CARBERRY THRU 92014 | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| DALVIR GILL | |||||||
| CHIEF EXECUTIVE OFFICER | 40.00 | Yes (X) | $1,177,000 | $0 | $35,799 | Yes (X) | |
| BERNHARDT ZEIHER | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| TAKUKO YAMADA-SAWADA | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| IRIS LOEW-FRIEDRICH | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| LYNN MARKS | |||||||
| CORPORATE SECRETARY | 0.50 | $0 | $0 | $0 | Yes (X) | ||
| MARTIN FITCHET THRU 52014 | |||||||
| TREASURER | 1.00 | $0 | $0 | $0 | Yes (X) | ||
| ANDREW LEE EFF 52014 | |||||||
| TREASURER | 1.00 | $0 | $0 | $0 | Yes (X) | ||
| JANICE CHANG | |||||||
| HEAD OF DELIVERY EXCELLENCE & CORP AFFAIRS | 40.00 | $337,019 | $0 | $16,620 | Yes (X) | ||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $1,514,019 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $52,419 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 2 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| ACCENTURE LLP | |||||
| 2005 MARKET STREET ONE COMMERCE SQ | PHILA | PA | 19103 | CONSULTING | $5,505,096 |
| KILPATRICK TOWNSEND | |||||
| 1114 AVENUE OF THE AMERICAS 21 | NEW YORK | NY | 10036 | LEGAL SERVICES | $1,416,012 |
| PENTICO SOLUTIONS INC | |||||
| 385 BODINE RD | BERWYN | PA | 19312 | CONSULTING | $412,731 |
| THE NORTH HIGHLAND COMPANY | |||||
| 3333 PIEDMONT RD | ATLANTA | GA | 30308 | CONSULTING | $377,698 |
| MAGIC HAT CONSULTING INC | |||||
| 455 PENNSYLVANIA AVENUE | FORT WASHINGTON | PA | 19034 | CONSULTING | $130,081 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 8 | CntrctRcvdGreaterThan100KCnt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | MEMBERSHIP DUES | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $15,276,176 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $15,276,176 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $15,276,176 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $17,212 | TotalRevenueColumnAmt |
| Exclusion | $17,212 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $15,293,388 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $15,276,176 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $17,212 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,566,438 | TotalAmt |
| Management And General | $1,566,438 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $379,049 | TotalAmt |
| Management And General | $379,049 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $22,460 | TotalAmt |
| Management And General | $22,460 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $46,211 | TotalAmt |
| Management And General | $46,211 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $37,974 | TotalAmt |
| Management And General | $37,974 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,416,012 | TotalAmt |
| Program Services | $893,546 | ProgramServicesAmt |
| Management And General | $522,466 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $104,667 | TotalAmt |
| Management And General | $104,667 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,212,948 | TotalAmt |
| Program Services | $6,496,728 | ProgramServicesAmt |
| Management And General | $716,220 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $21,900 | TotalAmt |
| Program Services | $21,900 | ProgramServicesAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $96,265 | TotalAmt |
| Program Services | $106 | ProgramServicesAmt |
| Management And General | $96,159 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $404,820 | TotalAmt |
| Program Services | $361,883 | ProgramServicesAmt |
| Management And General | $42,937 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $219,649 | TotalAmt |
| Program Services | $21,398 | ProgramServicesAmt |
| Management And General | $198,251 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $102,520 | TotalAmt |
| Program Services | $9,495 | ProgramServicesAmt |
| Management And General | $93,025 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,452 | TotalAmt |
| Management And General | $3,452 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $64,955 | TotalAmt |
| Program Services | $49,073 | ProgramServicesAmt |
| Management And General | $15,882 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|
| RECRUITING | $72,278 | $72,278 |
| FILING FEES | $3,555 | $3,555 |
| BOOKS, SUBSCRIPTIONS, R | $3,221 | $3,221 |
| DUES | $1,109 | $1,109 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $840 | TotalAmt |
| Management And General | $840 | ManagementAndGeneralAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,780,323 | TotalAmt |
| Program Services | $7,854,129 | ProgramServicesAmt |
| Management And General | $3,926,194 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,924,035 | BOYAmt |
| EOY | $4,236,350 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,505,325 | BOYAmt |
| EOY | $11,098,434 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,020,028 | BOYAmt |
| EOY | $19,500,000 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $40,326 | BOYAmt |
| EOY | $55,229 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $14,458 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $5,924 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $585,586 | BOYAmt |
| EOY | $8,534 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,075,300 | BOYAmt |
| EOY | $34,898,547 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $706,431 | BOYAmt |
| EOY | $2,086,391 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,196,176 | BOYAmt |
| EOY | $22,700,000 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,902,607 | BOYAmt |
| EOY | $24,786,391 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,172,693 | BOYAmt |
| EOY | $10,112,156 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,172,693 | BOYAmt |
| EOY | $10,112,156 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,075,300 | BOYAmt |
| EOY | $34,898,547 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $3,513,065 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | -$573,602 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | 0 | FSAuditedInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantially All Dues Nonded | 0 | SubstantiallyAllDuesNondedInd |
| Only In House Lobbying | Yes (1) | OnlyInHouseLobbyingInd |
| Agree Carryover Prior Year | 0 | AgreeCarryoverPriorYearInd |
Schedule D IRS990ScheduleD
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $4,202 | OtherCostOrOtherBasisAmt |
| Depreciation | $2,334 | DepreciationAmt |
| Book Value | $1,868 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $10,256 | OtherCostOrOtherBasisAmt |
| Depreciation | $3,590 | DepreciationAmt |
| Book Value | $6,666 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $8,534 | TotalBookValueLandBuildingsAmt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (2 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DALVIR GILL | ||||||||||||||
| CHIEF EXECUTIVE OFFICER | $865,000 | $0 | $312,000 | $0 | $0 | $0 | $0 | $0 | $35,799 | $0 | $1,212,799 | $0 | $0 | $0 |
| JANICE CHANG | ||||||||||||||
| HEAD OF DELIVERY EXCELLENCE & CORP A | $268,269 | $0 | $68,750 | $0 | $0 | $0 | $0 | $0 | $16,620 | $0 | $353,639 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 3 | FormAndLineReferenceDesc |
| Explanation | THE BOARD APPROVES THE COMPENSATION AND BONUS OF THE CEO. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (11 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 2 | TRANSCELERATE CURRENTLY HAS 12 INITIATIVES WHICH SHARE THE GOALS OF INCREASING EFFICIENCIES IN CLINICAL TRIALS, ENHANCING PATIENT SAFETY & ACCELERATING DEVELOPMENT TIMELINES. IN 2014, TRANSCELERATE APPROVED THREE ADDITIONAL INITIATIVES: CLINICAL DATA TRANSPARENCY: IN RESPONSE TO REGULATORY AGENCIES' PUSH FOR GREATER CLINICAL DATA TRANSPARENCY, TRANSCELERATE IS DEVELOPING A POSITION ON THE BEST AND MOST EFFICIENT METHODS FOR REDACTING PRIVACY INFORMATION FOUND IN CLINICAL STUDY REPORTS, AND AN APPROACH FOR THE ANONYMIZATION OF PATIENT LEVEL DATA SHARED WITH THE BROADER HEALTH CARE COMMUNITY. QUALITY MANAGEMENT SYSTEM: DEVELOP A FRAMEWORK SPECIFICALLY FOR CLINICAL RESEARCH TO IMPROVE THE QUALITY AND EFFICIENCY OF CLINICAL TRIALS. A QMS WILL ENHANCE PATIENT SAFETY BY IMPROVED QUALITY, ASSURE DATA INTEGRITY, MINIMIZE DELAYS IN CLINICAL TRIALS, AND BRING DRUGS TO MARKET MORE QUICKLY. PLACEBO / STANDARD OF CARE DATA SHARING: CURRENTLY, NO VEHICLE EXISTS TO MAXIMIZE VALUE OF CLINICAL DATA COLLECTED HISTORICALLY TO IMPROVE STUDY DESIGN, INTERPRET SAFETY SIGNALS CONTEXTUALLY AND IMPROVE SUBJECT RECRUITMENT. TRANSCELERATE IS SEEKING TO ESTABLISH A SOLUTION TO SHARE PLACEBO AND STANDARD OF CARE (SOC) DATA ACROSS PARTICIPATING MEMBER COMPANIES. THIS COULD LEAD TO IMPROVED CLINICAL TRIAL DESIGN, FASTER CLINICAL TRIAL EXECUTION, ENABLE A BETTER UNDERSTANDING OF DISEASES, AND IMPROVE THE PATIENT EXPERIENCE IN A CLINICAL TRIAL. |
| FORM 990, PART VI, SECTION A, LINE 4 | SECTION 2.01(A)(III) OF THE BYLAWS PREVIOUSLY PROVIDED THAT: "TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION OR BE AN EXTERNAL PARTNER OF PHARMACEUTICAL COMPANIES IN CLINICAL TRIALS." THE BOARD OF DIRECTORS VOTED TO AMEND THE BYLAWS TO PROVIDE THAT: "TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION." IN SECTION 2.01(B) OF THE BYLAWS, THE BOARD OF DIRECTORS VOTED TO AMEND THE BYLAWS TO ADD THE FOLLOWING LANGUAGE: "FOR PURPOSES OF DETERMINING AN APPLICANT'S MEMBERSHIP TIER, THE BOARD OF DIRECTORS OR ITS DESIGNEES SHALL CONSIDER AND TAKE INTO ACCOUNT THE ANNUAL RESEARCH AND DEVELOPMENT BUDGET FOR NOT ONLY THE PARTICULAR COMPANY APPLYING FOR MEMBERSHIP, BUT ALSO ANY ENTITY CONTROLLING, CONTROLLED BY, OR UNDER COMMON CONTROL WITH THE APPLICANT. (AND IN THIS CONTEXT, "CONTROL" SHALL MEAN DIRECT OR INDIRECT OWNERSHIP OF OR THE RIGHT TO EXERCISE: (I) GREATER THAN FIFTY PERCENT (50%) OF THE OUTSTANDING SHARES OR SECURITIES ENTITLED TO VOTE FOR THE ELECTION OF DIRECTORS OR SIMILAR MANAGING AUTHORITY OF THE SUBJECT ENTITY; OR (II) GREATER THAN FIFTY PERCENT (50%) OF THE OWNERSHIP INTEREST REPRESENTING THE RIGHT TO MAKE DECISIONS FOR THE SUBJECT ENTITY.)" IN SECTION 2.04(G) OF THE BYLAWS, THE BOARD OF DIRECTORS VOTED TO AMEND THE BYLAWS TO ADD THE FOLLOWING LANGUAGE: "MEMBERS MAY VOTE BY PROXY VIA TELEPHONIC OR ELECTRONIC MEANS AS PERMITTED BY THE BOARD." SECTION 3.02 OF THE BYLAWS PREVIOUSLY PROVIDED THAT: "THE INITIAL BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY (20) MEMBERS; PROVIDED THAT: A MINIMUM OF TWELVE (12) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE CHARTER MEMBERS (AS DESIGNATED AS SUCH BY THE BOARD OF DIRECTORS OF THE CORPORATION IN ITS SOLE DISCRETION) ("CHARTER MEMBER DIRECTORS") AND, IF SUCH NUMBER IS INCREASED IN THE FUTURE, THE REMAINDER OF SUCH SEATS RESERVED MAY BE FILLED BY TIER I MEMBERS THAT ARE NOT CHARTER MEMBERS ("TIER I DIRECTORS"); AT LEAST SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS ("TIER II DIRECTORS"); ONE (1) SEAT SHALL BE FILLED BY A DIRECTOR WHO IS A REPRESENTATIVE OF THE ASSOCIATE MEMBERS ("ASSOCIATE MEMBER DIRECTOR"); AND ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION "CEO DIRECTOR"). THE BOARD SEATS RESERVED FOR THE TIER I MEMBERS, INCLUDING THE CHARTER MEMBERS, SHALL AT ALL TIMES REPRESENT AT LEAST 55% OF THE TOTAL NUMBER OF DIRECTORS OF THE BOARD. IN THE EVENT THAT THE NUMBER OF DIRECTORS IS INCREASED TO MORE THAN SEVENTEEN (17) MEMBERS, THEN THE BOARD SEATS RESERVED FOR THE TIER I MEMBERS, INCLUDING THE CHARTER MEMBERS, AND THE BOARD SEATS RESERVED FOR THE TIER II MEMBERS SHALL BE INCREASED IN THE SAME RATIO AS SET FORTH ABOVE. THE BOARD OF DIRECTORS VOTED TO AMEND THE BYLAWS TO PROVIDE: "THE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY (20) MEMBERS; PROVIDED THAT (I) TEN (10) SEATS ARE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE CHARTER MEMBERS (AND EACH CHARTER MEMBER HAS DISCRETION TO APPOINT ITS OWN REPRESENTATIVE TO THE BOARD OF DIRECTORS) ("CHARTER MEMBER DIRECTORS"); (II) UP TO TWO (2) ADDITIONAL SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE NOT CHARTER MEMBERS ("AT LARGE TIER I DIRECTORS)(CHARTER MEMBER DIRECTORS AND AT LARGE TIER I DIRECTORS COLLECTIVELY REFERRED TO AS "TIER I DIRECTORS"); (III) UP TO SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS ("TIER II DIRECTORS"); (IV) ONE (1) SEAT SHALL BE FILLED BY A DIRECTOR WHO IS A REPRESENTATIVE OF THE ASSOCIATE MEMBERS ("ASSOCIATE MEMBER DIRECTOR"); AND (V) ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION ("CEO DIRECTOR"). THE BOARD SEATS RESERVED FOR THE TIER I MEMBERS, INCLUDING THE CHARTER MEMBERS, SHALL AT ALL TIMES REPRESENT AT LEAST 55% OF THE TOTAL NUMBER OF DIRECTORS OF THE BOARD. IN THE EVENT THAT THE NUMBER OF DIRECTORS IS INCREASED, THEN THE BOARD SEATS RESERVED FOR THE TIER I MEMBERS, INCLUDING THE CHARTER MEMBERS, AND THE BOARD SEATS RESERVED FOR THE TIER II MEMBERS SHALL BE INCREASED IN THE SAME RATIO AS SET FORTH ABOVE." IN SECTION 3.09 OF THE BYLAWS, THE BOARD OF DIRECTORS VOTED TO AMEND THE BYLAWS TO ADD THE FOLLOWING LANGUAGE: "SUCH WRITTEN CONSENT(S) MAY BE MADE BY ELECTRONIC TRANSMISSION, INCLUDING E-MAIL." |
| FORM 990, PART VI, SECTION A, LINE 6 | THE MEMBERS OF THE CORPORATION CONSIST OF SUCH FIRMS AND CORPORATIONS THAT ARE APPROVED FOR MEMBERSHIP FROM TIME TO TIME BY THE BOARD OF DIRECTORS OR ITS DESIGNEES IN ACCORDANCE WITH THE POLICIES AND PROCEDURES OF THE CORPORATION. THE CORPORATION HAS THE FOLLOWING CATEGORIES OF MEMBERS: A. TIER I MEMBERS - TO BE ELIGIBLE FOR TIER I MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT IN EXCESS OF $2.5 BILLION. ELIGIBILITY FOR TIER I MEMBERSHIP IS ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. THE INITIAL TIER 1 MEMBER ARE FURTHER DEFINED AS THE "CHARTER MEMBERS. B. TIER II MEMBERS - TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $100 MILLION. ELIGIBILITY FOR TIER II MEMBERSHIP WILL BE ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. C. ASSOCIATE MEMBERS - TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION OR BE AN EXTERNAL PARTNER OF PHARMACEUTICAL COMPANIES IN CLINICAL TRIALS. |
| FORM 990, PART VI, SECTION A, LINE 7A | THE CORPORATION'S BY-LAWS STATE THAT DIRECTORS SHALL BE ELECTED OR APPOINTED, AS APPLICABLE, ANNUALLY AT THE ANNUAL MEETING OF MEMBERS AND SHALL SERVE UNTIL THE FOLLOWING ANNUAL MEETING OF MEMBERS AND UNTIL THEIR SUCCESSORS ARE ELECTED OR APPOINTED, AS APPLICABLE, AND QUALIFIED. EACH CHARTER MEMBER SHALL HAVE THE RIGHT TO APPOINT A REPRESENTATIVE OF THE CHARTER MEMBER TO SERVE AS A CHARTER MEMBER DIRECTOR. TIER I DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER I MEMBERS, WHICH INCLUDE THE CHARTER MEMBERS. TIER II DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER II MEMBERS. THE ASSOCIATE MEMBER DIRECTOR SHALL BE ELECTED BY A PLURALITY VOTE OF THE ASSOCIATE MEMBERS. THE CEO DIRECTOR SHALL SERVE EX-OFFICIO, FOR SO LONG AS HE OR SHE SHALL HOLD THE OFFICE OF CHIEF EXECUTIVE OFFICER. |
| FORM 990, PART VI, SECTION A, LINE 7B | EACH TIER I MEMBER SHALL BE ENTITLED TO THREE (3) VOTES AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER 1 MEMBERS ARE ENTITLED TO VOTE. EACH TIER II MEMBER SHALL BE ENTITLED TO ONE (1) VOTE AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER II MEMBERS ARE ENTITLED TO VOTE. ASSOCIATE MEMBERS SHALL BE ENTITLED TO NOTICE OF AND TO ATTEND MEETINGS OF THE MEMBERS BUT SHALL NOT BE ENTITLED TO VOTE AT SUCH MEETINGS, PROVIDED HOWEVER, ASSOCIATE MEMBERS SHALL HAVE THE RIGHT TO CAST ONE (1) VOTE EACH WITH RESPECT TO THE ELECTION OF THE NOMINEE TO FILL THE ASSOCIATE MEMBER BOARD POSITION. NOTWITHSTANDING THE ABOVE, IN ORDER TO BE ELIGIBLE TO VOTE, A MEMBER MUST BE IN GOOD STANDING AND ITS DUES AND ASSESSMENTS PAID IN FULL. |
| FORM 990, PART VI, SECTION B, LINE 11 | THE FINANCE COMMITTEE AND MANAGEMENT REVIEW AND APPROVE THE FORM 990. THE FORM IS THEN DISTRIBUTED TO ALL MEMBERS OF THE BOARD FOR THEIR REVIEW BEFORE FILING WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE TRANSCELERATE BOARD OF DIRECTORS PREPARES AND APPROVES THE COMPENSATION PACKAGE FOR THE CEO. THE CEO APPROVES THE COMPENSATION FOR THE HEAD OF DELIVERY EXCELLENCE AND CORPORATE AFFAIRS, ALONG WITH ALL OTHER KEY EMPLOYEES. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART IX, LINE 11G | OUTSIDE CONTRACT - TECHNOLOGY CONSULTING SERVICES: PROGRAM SERVICE EXPENSES 991,632. MANAGEMENT AND GENERAL EXPENSES 687,220. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,678,852. CONSULTANTS -TECHNOLOGY CONSULTING SERVICES: PROGRAM SERVICE EXPENSES 2,951,074. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,951,074. CROSS WS FEES: PROGRAM SERVICE EXPENSES 2,554,022. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,554,022. MARKETING CONSULTANT - OUTSIDE CONSULTANT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 29,000. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 29,000. |
| FORM 990, PART XI, LINE 9: | WRITE OFF SOFTWARE COSTS AND CONTRIBUTED SERVICES PREVIOUSLY RECORDED -623,602. REVERSE DEPRECIATION TAKEN ON SOFTWARE 50,000. |
| FORM 990, PART VI, SECTION B, LINE 14 | THE ORGANIZATION DOES NOT HAVE A WRITTEN DOCUMENT RETENTION AND DESTRUCTION POLICY. A DOCUMENT RETENTION AND DESTRUCTION POLICY WILL BE DEVELOPED AND ADOPTED IN 2015. |